Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2012

View Archived Issues

New potential antibodies for anticancer use developed in U.S.

Potent novel ALK inhibitors presented

New dual allosteric Akt inhibitors show promise in cancer models

Antiglaucoma agent ATS-8535 characterized in vitro and in vivo

Novel HealOr product accelerates corneal healing

CNK1 PH domain investigated as a target for KRas-mutant cancer

Mitsubishi Tanabe Pharma reviews highlights of fiscal 2011

Research in U.K. links SNP to systemic sclerosis risk

Japanese phase II study of ONO-2745 completed

FDA committee votes on approval of Quad regimen

Phytopharm reports on preclinical Myogane study

Depomed receives milestone payment from Ironwood Pharmaceuticals

Kancera compounds show promise in cancer treatment

Theratechnologies' TH-1173 enters preclinical safety phase

Arno Therapeutics product obtains orphan drug status for NF2

New data presented on brentuximab vedotin in cutaneous T-cell lymphoma

Proximagen designs novel chemokine CXCR4 receptor antagonists

Novel OSM-directed antibodies created at Janssen Biotech

AstraZeneca presents new transient receptor potential TRPA1 channel antagonists

Research at Amicus yields new pharmacological chaperones

Novel candidate drugs for Alzheimer's disease patented

Islet Sciences licenses technology from Yale University

Galapagos kicks off new study of novel JAK1 inhibitor

Health Canada grants Apricus Biosciences meeting for nail fungus therapy

Mologen study meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...